Invention Grant
US08436185B2 Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
有权
2- {4 - [(3S) - 哌啶-3-基]苯基} -2H-吲唑-7-甲酰胺的药学上可接受的盐
- Patent Title: Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
- Patent Title (中): 2- {4 - [(3S) - 哌啶-3-基]苯基} -2H-吲唑-7-甲酰胺的药学上可接受的盐
-
Application No.: US12811922Application Date: 2009-01-08
-
Publication No.: US08436185B2Publication Date: 2013-05-07
- Inventor: Jennifer R. Foley , Robert Darrin Wilson
- Applicant: Jennifer R. Foley , Robert Darrin Wilson
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Yong Zhao; David A. Muthard; Matthew A. Leff
- International Application: PCT/GB2009/000041 WO 20090108
- International Announcement: WO2009/087381 WO 20090716
- Main IPC: C07D211/32
- IPC: C07D211/32 ; A61K31/445
![Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide](/abs-image/US/2013/05/07/US08436185B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl) transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA-damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.
Public/Granted literature
- US20100286203A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE Public/Granted day:2010-11-11
Information query